• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Our Bureau

BANGALORE, Dec. 19

HIMALAYA Herbal Healthcare has entered the domestic market for prostate enlargement treatment with Himplasia.

The drug is a clinically proven combination of five time-tested herbs and offers double-pronged action of an alpha blocker as well as a finasteride and without side-effects, according to Mr Philipe J. Haydon, General Manager — Pharma Marketing, of the Rs 250-company.

Himplasia is the Himalaya's sixth product targeted at men. It has met with a favourable market abroad and can rake in a potential five per cent market share in the remaining three months of this year, Mr Haydon said.

Prostate enlargement or benign prostate hyperplasia (BPH) has Rs 60-crore domestic market (as per ORG September 2002 figures) with major allopathy players such as Pfizer and Abbot operating in the Rs 47.50-crore alpha blocker segment, and Dr Reddy's and Cipla in the finasteride arena.

BPH is known to affect 25 per cent of men over 40 years of age and almost a third of those over 65 years. As per 2001 figures, over 77 million men have the condition, which may lead to hospitalisation and surgery.

Himplasia, according to Mr Haydon, is the first drug of its kind that reduces the gland size as well as treats attendant problems of the benign enlargement, which include painful urination, incontinence and impotence.

The tablets cost Rs 3 each and are available in packs of 30.

Send this article to Friends by E-Mail
Comment on this article to BLFeedback@thehindu.co.in

Stories in this Section
Himalaya Herbal launches prostate drug

Copyright © 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line